Awareness and recognition of the effectiveness of Acoustic CR® Neuromodulation continues to increase with the publication of clinical trial results in Restorative Neurology & Neuroscience.
The trial, led by Professor Peter Tass, found that Acoustic CR® Neuromodulation, which targets the neurological causes of tinnitus, benefited 7 in 10 patients – making it the first treatment to demonstrate clinical benefit.
Patients treated with Acoustic CR® Neuromodulation experienced a significant and clinically relevant decrease of both loudness and annoyance of tinnitus within just 12 weeks compared to patients who received a placebo. EEG results also showed that patients who were being treated with Acoustic CR® Neuromodulation moved towards a normal state EEG following treatment.
Our Prinicipal Audiologist, Mark Williams, writes: “This landmark academic paper by Professor Peter Tass is the first trial for Acoustic CR® Neuromodulation, and its results are extremely encouraging. As the first treatment for tinnitus to remove rather than mask symptoms, clinical evidence of safety and efficacy will hopefully open up this treatment to a wider range of patients.”
